Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies.

Mateos MV, Spencer A, Nooka AK, Pour L, Weisel K, Cavo M, Laubach JP, Cook G, Iida S, Benboubker L, Usmani SZ, Yoon SS, Bahlis NJ, Chiu C, Ukropec J, Schecter JM, Qin X, O' Rourke L, Dimopoulos MA.

Haematologica. 2019 Jun 20. pii: haematol.2019.217448. doi: 10.3324/haematol.2019.217448. [Epub ahead of print]

2.

Slow lenalidomide desensitization protocol for patients with multiple myeloma: case series from a single center.

Yau P, Jimenez-Zepeda VH, Bailey K, Duggan P, Tay J, Bahlis NJ, Neri P, McCulloch S.

Leuk Lymphoma. 2019 Jun 13:1-5. doi: 10.1080/10428194.2019.1627537. [Epub ahead of print]

PMID:
31190585
3.

From Inhibition to Degradation: Targeting the Antiapoptotic Protein Myeloid Cell Leukemia 1 (MCL1).

Papatzimas JW, Gorobets E, Maity R, Muniyat MI, MacCallum JL, Neri P, Bahlis NJ, Derksen DJ.

J Med Chem. 2019 Jun 13;62(11):5522-5540. doi: 10.1021/acs.jmedchem.9b00455. Epub 2019 Jun 4.

PMID:
31117518
4.

Multiple myeloma immunoglobulin lambda translocations portend poor prognosis.

Barwick BG, Neri P, Bahlis NJ, Nooka AK, Dhodapkar MV, Jaye DL, Hofmeister CC, Kaufman JL, Gupta VA, Auclair D, Keats JJ, Lonial S, Vertino PM, Boise LH.

Nat Commun. 2019 Apr 23;10(1):1911. doi: 10.1038/s41467-019-09555-6.

5.

Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma.

Matulis SM, Gupta VA, Neri P, Bahlis NJ, Maciag P, Leverson JD, Heffner LT Jr, Lonial S, Nooka AK, Kaufman JL, Boise LH.

Leukemia. 2019 May;33(5):1291-1296. doi: 10.1038/s41375-018-0374-8. Epub 2019 Jan 24. No abstract available.

PMID:
30679802
6.

Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma.

Bahlis NJ, Sutherland H, White D, Sebag M, Lentzsch S, Kotb R, Venner CP, Gasparetto C, Del Col A, Neri P, Reece D, Kauffman M, Shacham S, Unger TJ, Jeha J, Saint-Martin JR, Shah J, Chen C.

Blood. 2018 Dec 13;132(24):2546-2554. doi: 10.1182/blood-2018-06-858852. Epub 2018 Oct 23.

7.

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX.

Dimopoulos MA, San-Miguel J, Belch A, White D, Benboubker L, Cook G, Leiba M, Morton J, Ho PJ, Kim K, Takezako N, Moreau P, Kaufman JL, Sutherland HJ, Lalancette M, Magen H, Iida S, Kim JS, Prince HM, Cochrane T, Oriol A, Bahlis NJ, Chari A, O'Rourke L, Wu K, Schecter JM, Casneuf T, Chiu C, Soong D, Sasser AK, Khokhar NZ, Avet-Loiseau H, Usmani SZ.

Haematologica. 2018 Dec;103(12):2088-2096. doi: 10.3324/haematol.2018.194282. Epub 2018 Sep 20.

8.

Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma.

Leleu X, Masszi T, Bahlis NJ, Viterbo L, Baker B, Gimsing P, Maisnar V, Samoilova O, Rosiñol L, Langer C, Song K, Izumi T, Cleeland C, Berg D, Lin HM, Zhu Y, Skacel T, Moreau P, Richardson PG.

Am J Hematol. 2018 May 4. doi: 10.1002/ajh.25134. [Epub ahead of print]

9.

Early Relapse for Multiple Myeloma Patients Undergoing Single Autologous Stem Cell Therapy: A Single-center Experience.

Lee H, Duggan P, Chaudhry A, Neri P, Tay J, Rashid-Kolvear F, Bahlis NJ, Jimenez-Zepeda VH.

Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):e69-e75. doi: 10.1016/j.clml.2017.10.009. Epub 2017 Nov 1.

PMID:
29158114
10.

Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma.

Facon T, Dimopoulos MA, Dispenzieri A, Catalano JV, Belch A, Cavo M, Pinto A, Weisel K, Ludwig H, Bahlis NJ, Banos A, Tiab M, Delforge M, Cavenagh JD, Geraldes C, Lee JJ, Chen C, Oriol A, De La Rubia J, White D, Binder D, Lu J, Anderson KC, Moreau P, Attal M, Perrot A, Arnulf B, Qiu L, Roussel M, Boyle E, Manier S, Mohty M, Avet-Loiseau H, Leleu X, Ervin-Haynes A, Chen G, Houck V, Benboubker L, Hulin C.

Blood. 2018 Jan 18;131(3):301-310. doi: 10.1182/blood-2017-07-795047. Epub 2017 Nov 17.

11.

Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients.

Avet-Loiseau H, Bahlis NJ, Chng WJ, Masszi T, Viterbo L, Pour L, Ganly P, Palumbo A, Cavo M, Langer C, Pluta A, Nagler A, Kumar S, Ben-Yehuda D, Rajkumar SV, San-Miguel J, Berg D, Lin J, van de Velde H, Esseltine DL, di Bacco A, Moreau P, Richardson PG.

Blood. 2017 Dec 14;130(24):2610-2618. doi: 10.1182/blood-2017-06-791228. Epub 2017 Oct 20.

12.

Multiple myeloma cells sent "PAKing"!

Neri P, Bahlis NJ.

Blood. 2017 Apr 20;129(16):2208-2209. doi: 10.1182/blood-2017-02-764662. No abstract available.

13.

Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial.

Bahlis NJ, Corso A, Mugge LO, Shen ZX, Desjardins P, Stoppa AM, Decaux O, de Revel T, Granell M, Marit G, Nahi H, Demuynck H, Huang SY, Basu S, Guthrie TH, Ervin-Haynes A, Marek J, Chen G, Facon T.

Leukemia. 2017 Nov;31(11):2435-2442. doi: 10.1038/leu.2017.111. Epub 2017 Apr 4.

14.

Minimal residual disease (MRD) assessment by flow cytometry after ASCT for AL amyloidosis: are we there yet?

Lee H, Duggan P, Neri P, Tay J, Bahlis NJ, Jimenez-Zepeda VH.

Bone Marrow Transplant. 2017 Jun;52(6):915-917. doi: 10.1038/bmt.2017.28. Epub 2017 Mar 13. No abstract available.

PMID:
28287637
15.

Bortezomib-containing regimens (BCR) for the treatment of non-transplant eligible multiple myeloma.

Jimenez-Zepeda VH, Duggan P, Neri P, Tay J, Bahlis NJ.

Ann Hematol. 2017 Mar;96(3):431-439. doi: 10.1007/s00277-016-2901-x. Epub 2017 Jan 10.

PMID:
28074255
16.

New Strategies in Multiple Myeloma: Immunotherapy as a Novel Approach to Treat Patients with Multiple Myeloma.

Neri P, Bahlis NJ, Lonial S.

Clin Cancer Res. 2016 Dec 15;22(24):5959-5965. Epub 2016 Oct 19. Review.

17.

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, Rabin N, Orlowski RZ, Komarnicki M, Suzuki K, Plesner T, Yoon SS, Ben Yehuda D, Richardson PG, Goldschmidt H, Reece D, Lisby S, Khokhar NZ, O'Rourke L, Chiu C, Qin X, Guckert M, Ahmadi T, Moreau P; POLLUX Investigators.

N Engl J Med. 2016 Oct 6;375(14):1319-1331.

18.

Treatment of Relapsed/Refractory Multiple Myeloma.

Neri P, Bahlis NJ, Paba-Prada C, Richardson P.

Cancer Treat Res. 2016;169:169-194. Review.

PMID:
27696263
19.

Bortezomib-induced heat shock response protects multiple myeloma cells and is activated by heat shock factor 1 serine 326 phosphorylation.

Shah SP, Nooka AK, Jaye DL, Bahlis NJ, Lonial S, Boise LH.

Oncotarget. 2016 Sep 13;7(37):59727-59741. doi: 10.18632/oncotarget.10847.

20.

Revised International Staging System Applied to Real World Multiple Myeloma Patients.

Jimenez-Zepeda VH, Duggan P, Neri P, Rashid-Kolvear F, Tay J, Bahlis NJ.

Clin Lymphoma Myeloma Leuk. 2016 Sep;16(9):511-518. doi: 10.1016/j.clml.2016.06.001. Epub 2016 Jun 8.

PMID:
27425179
21.

A pharmacogenetic analysis of the Canadian Cancer Trials Group MY.10 clinical trial of maintenance therapy for multiple myeloma.

Han M, Murugesan A, Bahlis NJ, Song K, White D, Chen C, Seftel MD, Howsen-Jan K, Reece D, Stewart K, Xie Y, Hay AE, Shepherd L, Djurfeldt M, Zhu L, Meyer RM, Chen BE, Reiman T.

Blood. 2016 Aug 4;128(5):732-5. doi: 10.1182/blood-2016-06-716902. Epub 2016 Jun 23. No abstract available.

22.

Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma.

Usmani SZ, Weiss BM, Plesner T, Bahlis NJ, Belch A, Lonial S, Lokhorst HM, Voorhees PM, Richardson PG, Chari A, Sasser AK, Axel A, Feng H, Uhlar CM, Wang J, Khan I, Ahmadi T, Nahi H.

Blood. 2016 Jul 7;128(1):37-44. doi: 10.1182/blood-2016-03-705210. Epub 2016 May 23.

23.

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Simpson DR, Gimsing P, Palumbo A, Garderet L, Cavo M, Kumar S, Touzeau C, Buadi FK, Laubach JP, Berg DT, Lin J, Di Bacco A, Hui AM, van de Velde H, Richardson PG; TOURMALINE-MM1 Study Group.

N Engl J Med. 2016 Apr 28;374(17):1621-34. doi: 10.1056/NEJMoa1516282.

24.

MMSET/WHSC1 enhances DNA damage repair leading to an increase in resistance to chemotherapeutic agents.

Shah MY, Martinez-Garcia E, Phillip JM, Chambliss AB, Popovic R, Ezponda T, Small EC, Will C, Phillip MP, Neri P, Bahlis NJ, Wirtz D, Licht JD.

Oncogene. 2016 Nov 10;35(45):5905-5915. doi: 10.1038/onc.2016.116. Epub 2016 Apr 25.

25.

Bortezomib-Containing Regimens for the Treatment of Newly Diagnosed and Relapsed Amyloid Light Chain Amyloidosis: A Single-Center Experience.

Jimenez-Zepeda VH, Duggan P, Neri P, Bahlis NJ.

Clin Lymphoma Myeloma Leuk. 2016 Jun;16(6):e79-84. doi: 10.1016/j.clml.2016.03.005. Epub 2016 Mar 29.

PMID:
27101985
26.

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.

Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, Belch A, Krishnan A, Vescio RA, Mateos MV, Mazumder A, Orlowski RZ, Sutherland HJ, Bladé J, Scott EC, Oriol A, Berdeja J, Gharibo M, Stevens DA, LeBlanc R, Sebag M, Callander N, Jakubowiak A, White D, de la Rubia J, Richardson PG, Lisby S, Feng H, Uhlar CM, Khan I, Ahmadi T, Voorhees PM.

Lancet. 2016 Apr 9;387(10027):1551-1560. doi: 10.1016/S0140-6736(15)01120-4. Epub 2016 Jan 7.

PMID:
26778538
27.

Bortezomib and melphalan conditioning increases the rate of complete response and MRD negativity for patients with multiple myeloma undergoing single autologous stem cell transplant.

Jimenez-Zepeda VH, Duggan P, Neri P, Chaudhry A, Murray K, Culham M, Luider J, Fourie T, Rashid-Kolvear F, Bahlis NJ.

Leuk Lymphoma. 2016;57(4):973-6. doi: 10.3109/10428194.2015.1085534. Epub 2015 Oct 8. No abstract available.

PMID:
26450458
28.

A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191.

Hay AE, Murugesan A, DiPasquale AM, Kouroukis T, Sandhu I, Kukreti V, Bahlis NJ, Lategan J, Reece DE, Lyons JF, Sederias J, Xu H, Powers J, Seymour LK, Reiman T.

Leuk Lymphoma. 2016;57(6):1463-6. doi: 10.3109/10428194.2015.1091927. Epub 2015 Oct 15. No abstract available.

PMID:
26376958
29.

Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone.

Dimopoulos MA, Weisel KC, Song KW, Delforge M, Karlin L, Goldschmidt H, Moreau P, Banos A, Oriol A, Garderet L, Cavo M, Ivanova V, Alegre A, Martinez-Lopez J, Chen C, Spencer A, Knop S, Bahlis NJ, Renner C, Yu X, Hong K, Sternas L, Jacques C, Zaki MH, San Miguel JF.

Haematologica. 2015 Oct;100(10):1327-33. doi: 10.3324/haematol.2014.117077. Epub 2015 Aug 6.

30.

Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma.

San Miguel JF, Weisel KC, Song KW, Delforge M, Karlin L, Goldschmidt H, Moreau P, Banos A, Oriol A, Garderet L, Cavo M, Ivanova V, Alegre A, Martinez-Lopez J, Chen C, Renner C, Bahlis NJ, Yu X, Teasdale T, Sternas L, Jacques C, Zaki MH, Dimopoulos MA.

Haematologica. 2015 Oct;100(10):1334-9. doi: 10.3324/haematol.2015.125864. Epub 2015 Jul 9.

31.

Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide.

Delforge M, Minuk L, Eisenmann JC, Arnulf B, Canepa L, Fragasso A, Leyvraz S, Langer C, Ezaydi Y, Vogl DT, Giraldo-Castellano P, Yoon SS, Zarnitsky C, Escoffre-Barbe M, Lemieux B, Song K, Bahlis NJ, Guo S, Monzini MS, Ervin-Haynes A, Houck V, Facon T.

Haematologica. 2015 Jun;100(6):826-33. doi: 10.3324/haematol.2014.120121. Epub 2015 Mar 13.

32.

A novel transthyretin variant p.H110D (H90D) as a cause of familial amyloid polyneuropathy in a large Irish kindred.

Jimenez-Zepeda VH, Bahlis NJ, Gilbertson J, Rendell N, Porcari R, Lachmann HJ, Gillmore JD, Hawkins PN, Rowczenio DM.

Amyloid. 2015 Mar;22(1):26-30. doi: 10.3109/13506129.2014.987377. Epub 2014 Nov 28.

PMID:
25430583
33.

The Tao of myeloma.

Boise LH, Kaufman JL, Bahlis NJ, Lonial S, Lee KP.

Blood. 2014 Sep 18;124(12):1873-9. Review.

34.

Results of a prospective phase II trial evaluating interim positron emission tomography-guided high dose therapy for poor prognosis diffuse large B-cell lymphoma.

Stewart DA, Kloiber R, Owen C, Bahlis NJ, Duggan P, Mansoor A, Bence-Bruckler I.

Leuk Lymphoma. 2014 Sep;55(9):2064-70. doi: 10.3109/10428194.2013.862242. Epub 2014 Feb 17.

PMID:
24188476
35.

Pinning down myeloma with Pim2 inhibitors!

Neri P, Bahlis NJ.

Blood. 2013 Aug 29;122(9):1534-6. doi: 10.1182/blood-2013-07-514091. No abstract available.

36.

Establishing a target exposure for once-daily intravenous busulfan given with fludarabine and thymoglobulin before allogeneic transplantation.

Russell JA, Kangarloo SB, Williamson T, Chaudhry MA, Savoie ML, Turner AR, Larratt L, Storek J, Bahlis NJ, Shafey M, Brown CB, Yang M, Geddes M, Zacarias N, Yue P, Duggan P, Stewart DA, Daly A.

Biol Blood Marrow Transplant. 2013 Sep;19(9):1381-6. doi: 10.1016/j.bbmt.2013.07.002. Epub 2013 Jul 17. Erratum in: Biol Blood Marrow Transplant. 2014 Feb;20(2):290.

37.

Genomic instability in multiple myeloma: mechanisms and therapeutic implications.

Neri P, Bahlis NJ.

Expert Opin Biol Ther. 2013 Jun;13 Suppl 1:S69-82. doi: 10.1517/14712598.2013.814637. Epub 2013 Jun 19. Review.

PMID:
23782016
38.

High dose salvage therapy with dose intensive cyclophosphamide, etoposide and cisplatin may increase transplant rates for relapsed/refractory aggressive non-Hodgkin lymphoma.

Vijay A, Duan Q, Henning JW, Duggan P, Daly A, Shafey M, Bahlis NJ, Stewart DA.

Leuk Lymphoma. 2013 Dec;54(12):2620-6. doi: 10.3109/10428194.2013.783211. Epub 2013 Apr 16.

PMID:
23472969
39.

A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial.

Stewart AK, Trudel S, Bahlis NJ, White D, Sabry W, Belch A, Reiman T, Roy J, Shustik C, Kovacs MJ, Rubinger M, Cantin G, Song K, Tompkins KA, Marcellus DC, Lacy MQ, Sussman J, Reece D, Brundage M, Harnett EL, Shepherd L, Chapman JA, Meyer RM.

Blood. 2013 Feb 28;121(9):1517-23. doi: 10.1182/blood-2012-09-451872. Epub 2013 Jan 7.

40.

Lenalidomide plus melphalan without prednisone for previously untreated older patients with multiple myeloma: a phase II trial.

White DJ, Bahlis NJ, Marcellus DC, Belch A, Stewart AK, Chen C, Kovacs MJ, Macdonald DA, Reece DE, Reiman T, Harnett E, Meyer RM, Chapman JA, Couban S.

Clin Lymphoma Myeloma Leuk. 2013 Feb;13(1):19-24. doi: 10.1016/j.clml.2012.08.009. Epub 2012 Nov 7.

PMID:
23141150
41.

Darwinian evolution and tiding clones in multiple myeloma.

Bahlis NJ.

Blood. 2012 Aug 2;120(5):927-8. doi: 10.1182/blood-2012-06-430645.

42.

Targeting of adhesion molecules as a therapeutic strategy in multiple myeloma.

Neri P, Bahlis NJ.

Curr Cancer Drug Targets. 2012 Sep;12(7):776-96. Review.

PMID:
22671924
43.

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma.

Vij R, Wang M, Kaufman JL, Lonial S, Jakubowiak AJ, Stewart AK, Kukreti V, Jagannath S, McDonagh KT, Alsina M, Bahlis NJ, Reu FJ, Gabrail NY, Belch A, Matous JV, Lee P, Rosen P, Sebag M, Vesole DH, Kunkel LA, Wear SM, Wong AF, Orlowski RZ, Siegel DS.

Blood. 2012 Jun 14;119(24):5661-70. doi: 10.1182/blood-2012-03-414359. Epub 2012 May 3.

44.

Panobinostat for the treatment of multiple myeloma.

Neri P, Bahlis NJ, Lonial S.

Expert Opin Investig Drugs. 2012 May;21(5):733-47. doi: 10.1517/13543784.2012.668883. Epub 2012 Mar 12. Review.

PMID:
22404247
45.

Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors.

Neri P, Ren L, Gratton K, Stebner E, Johnson J, Klimowicz A, Duggan P, Tassone P, Mansoor A, Stewart DA, Lonial S, Boise LH, Bahlis NJ.

Blood. 2011 Dec 8;118(24):6368-79. doi: 10.1182/blood-2011-06-363911. Epub 2011 Sep 13.

46.

A prospective phase II study of RICE re-induction, then high-dose fludarabine and busulfan, followed by autologous or allogeneic blood stem cell transplantation for indolent b-cell lymphoma.

Stewart DA, Duan Q, Carlson L, Russell JA, Bahlis NJ, Duggan P, Hasegawa W, Voralia M.

Clin Lymphoma Myeloma Leuk. 2011 Dec;11(6):475-82. doi: 10.1016/j.clml.2011.06.012. Epub 2011 Aug 10.

PMID:
21831743
47.

Development and validation of a test dose strategy for once-daily i.v. busulfan: importance of fixed infusion rate dosing.

Kangarloo SB, Naveed F, Ng ES, Chaudhry MA, Wu J, Bahlis NJ, Brown CB, Daly A, Duggan P, Geddes M, Quinlan D, Savoie ML, Shafey M, Stewart DA, Storek J, Yang M, Zacarias N, Yue P, Magliocco AM, Russell JA.

Biol Blood Marrow Transplant. 2012 Feb;18(2):295-301. doi: 10.1016/j.bbmt.2011.07.015. Epub 2011 Jul 27.

48.

Integrin β7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion.

Neri P, Ren L, Azab AK, Brentnall M, Gratton K, Klimowicz AC, Lin C, Duggan P, Tassone P, Mansoor A, Stewart DA, Boise LH, Ghobrial IM, Bahlis NJ.

Blood. 2011 Jun 9;117(23):6202-13. doi: 10.1182/blood-2010-06-292243. Epub 2011 Apr 7.

49.

Influence of comorbidities on transplant outcomes in patients aged 50 years or more after myeloablative conditioning incorporating fludarabine, BU and ATG.

El Kourashy S, Williamson T, Chaudhry MA, Savoie ML, Turner AR, Larratt L, Storek J, Bahlis NJ, Brown CB, Yang M, Quinlan D, Geddes M, Zacarias N, Daly A, Duggan P, Stewart DA, Russell JA.

Bone Marrow Transplant. 2011 Aug;46(8):1077-83. doi: 10.1038/bmt.2010.257. Epub 2010 Nov 8.

PMID:
21057555
50.

The addition of 400 cGY total body irradiation to a regimen incorporating once-daily intravenous busulfan, fludarabine, and antithymocyte globulin reduces relapse without affecting nonrelapse mortality in acute myelogenous leukemia.

Russell JA, Irish W, Balogh A, Chaudhry MA, Savoie ML, Turner AR, Larratt L, Storek J, Bahlis NJ, Brown CB, Quinlan D, Geddes M, Zacarias N, Daly A, Duggan P, Stewart DA.

Biol Blood Marrow Transplant. 2010 Apr;16(4):509-14. doi: 10.1016/j.bbmt.2009.11.017. Epub 2009 Dec 3.

Supplemental Content

Loading ...
Support Center